13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
35 檔
38.4%
As reported in its official Q1 2024 Form 13F filing, Novo Holdings A/S's tracked investment portfolio stood at $1.7B with 35 total positions.
In Q1 2024, Novo Holdings A/S adopted a defensive or profit-taking posture, trimming 8 positions and completely liquidating 6 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including ASML, BN, CRM) accounted for 38.4% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASML | ASML Holding N.V. | Stock-Tech | 12.22% | +0.81% | -7.70% | |
| 2 | BN | Brookfield CORP | Stock-Financials | 11.21% | -2.78% | — | |
| 3 | CRM | Salesforce Inc | Stock-Tech | 9.98% | -2.37% | -9.49% | |
| 4 | EPC | Edgewell Personal Care Co | Stock-Other | 7.98% | — | — | |
| 5 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 4.19% | — | — | |
| 6 | PCVX | Vaxcyte Inc | Stock-Other | 3.98% | -1.35% | — | |
| 7 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.55% | -1.69% | -0.13% | |
| 8 | CABO | Cable One Inc | Stock-Comm Services | 3.46% | — | — | |
| 9 | ✓ | Lanzatech Global Inc | Stock-Other | 3.38% | — | — | |
| 10 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 3.08% | -0.24% | -6.67% | |
| 11 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.71% | -3.02% | EXIT | |
| 12 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.60% | -2.27% | — | |
| 13 | INSM | Insmed Inc | Stock-Healthcare | 2.51% | +0.75% | NEW | |
| 14 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 2.50% | -1.19% | — | |
| 15 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.35% | — | -0.14% | |
| 16 | AAPL | Apple Inc | Stock-Tech | 2.16% | — | -17.38% | |
| 17 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.03% | — | — | |
| 18 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 1.95% | — | — | |
| 19 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.92% | — | — | |
| 20 | PHVS | Pharvaris N.V. | Stock-Other | 1.86% | -1.20% | -24.12% | |
| 21 | ✓ | Verve Therapeutics Inc | Stock-Other | 1.83% | — | — | |
| 22 | BAM | Brookfield Asset Mgmt-a | Stock-Financials | 1.82% | — | — | |
| 23 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 1.77% | — | +25.27% | |
| 24 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.33% | -0.89% | — | |
| 25 | AVBP | Arrivent Biopharma Inc | Stock-Other | 1.33% | -0.60% | — | |
| 26 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 1.27% | — | — | |
| 27 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.22% | — | — | |
| 28 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 1.20% | — | — | |
| 29 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.97% | — | — | |
| 30 | IOBTQ | Io Biotech Inc | Stock-Other | 0.61% | — | -11.46% | |
| 31 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.35% | — | — | |
| 32 | TMCI | Treace Medical Concepts Inc | Stock-Other | 0.32% | — | — | |
| 33 | MQ | Marqeta Inc-a | Stock-Other | 0.18% | +0.27% | — | |
| 34 | GLTOUSD | Damora Therapeutics Inc | Stock-Other | 0.13% | — | — | |
| 35 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.06% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EPC | Edgewell Personal Care Co | +8% | NEW | New buy |
| 2 | ASML | ASML Holding N.V. | +3% | -7.70% | Trim |
| 3 | BN | Brookfield CORP | +1.6% | — | Unchanged |
| 4 | CRM | Salesforce Inc | +1.4% | -9.49% | Trim |
| 5 | VRDN | Viridian Therapeutics Inc | +1.3% | NEW | New buy |
| 6 | AVBP | Arrivent Biopharma Inc | +1.3% | NEW | New buy |
| 7 | MGX | Metagenomi Therapeutics Inc | +1.3% | NEW | New buy |
| 8 | KYTX | Kyverna Therapeutics Inc | +1.2% | NEW | New buy |
| 9 | FDMT | 4d Molecular Therapeutics In | +1.2% | -6.67% | Trim |
| 10 | CRNX | Crinetics Pharmaceuticals In | +1.1% | -0.13% | Trim |
| 11 | PCVX | Vaxcyte Inc | +0.7% | — | Unchanged |
| 12 | LXEO | Lexeo Therapeutics Inc | +0.7% | +25.27% | Add |
| 13 | 2655787D | Blueprint Medicines CORP | +0.3% | -0.14% | Trim |
| 14 | BAM | Brookfield Asset Mgmt-a | +0.3% | — | Unchanged |
| 15 | INSP | Inspire Medical Systems Inc | +0.2% | — | Unchanged |
| 16 | CRGX | Cargo Therapeutics Inc | +0.1% | — | Unchanged |
| 17 | ✓ | Verve Therapeutics Inc | +0.1% | — | Unchanged |
| 18 | BABA | Alibaba Group Holding-sp Adr | +0.1% | — | Unchanged |
| 19 | TMCI | Treace Medical Concepts Inc | 0% | — | Unchanged |
| 20 | BMRN | Biomarin Pharmaceutical Inc | 0% | — | Unchanged |
| 21 | GLTOUSD | Damora Therapeutics Inc | 0% | — | Unchanged |
| 22 | RCKT | Rocket Pharmaceuticals Inc | 0% | — | Unchanged |
| 23 | MQ | Marqeta Inc-a | 0% | — | Unchanged |
| 24 | INSM | Insmed Inc | -0.1% | — | Unchanged |
| 25 | ABCL | Abcellera Biologics Inc | -0.1% | — | Unchanged |
| 26 | IOBTQ | Io Biotech Inc | -0.1% | -11.46% | Trim |
| 27 | MIRM | Mirum Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 28 | AM6 | Amicus Therapeutics Inc | -0.2% | — | Unchanged |
| 29 | ALNY | Alnylam Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 30 | ✓ | Lava Therapeutics NV | -0.2% | EXIT | Sold out |
| 31 | ✓ | Rallybio CORP | -0.3% | EXIT | Sold out |
| 32 | AAPL | Apple Inc | -0.5% | -17.38% | Trim |
| 33 | CABO | Cable One Inc | -0.6% | — | Unchanged |
| 34 | CORT | Corcept Therapeutics Inc | -0.7% | — | Unchanged |
| 35 | PHVS | Pharvaris N.V. | -0.8% | -24.12% | Trim |
| 36 | SPRU | Spruce Power Holding Corporation | -1.2% | EXIT | Sold out |
| 37 | CBAYUSD | Cymabay Therapeutics Inc | -1.3% | EXIT | Sold out |
| 38 | ✓ | Lanzatech Global Inc | -1.5% | — | Unchanged |
| 39 | EWTX | Edgewise Therapeutics Inc | -4.1% | EXIT | Sold out |
| 40 | TSM | Taiwan Semiconductor-sp Adr | -4.6% | EXIT | Sold out |
| 41 | SPRO | Spero Therapeutics Inc | -7.6% | — | Unchanged |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 35 disclosed positions in Q1 2024.
During Q1 2024, Novo Holdings A/S's top holdings by market value included ASML (12.2%)、BN (11.2%)、CRM (10.0%). The largest single position, ASML, represented 12.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
EPC
市值: $115.7M
Top Position Liquidated / Trimmed
TSM
前期市值: $73.9M
In Q1 2024, Novo Holdings A/S made 20 total portfolio adjustments, initiating 5 new buys, adding to 1 positions, trimming 8 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.